EAGLE PHARMACEUTICALS, INC.
EGRXDrugs in Pipeline
5
Phase 3 Programs
2
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
Ryanodex and Standard of Care
Exertional Heat Stroke
Mesalamine
Mild to Moderate Ulcerative Colitis
CAL02
Pneumonia, Bacterial
Dantrolene sodium for injectable suspension
Heat Stroke
SeeMore(TM)
Myocardial Infarction
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Ryanodex and Standard of Care | Phase 3 | Exertional Heat Stroke | - | - |
Mesalamine | Phase 3 | Mild to Moderate Ulcerative Colitis | - | - |
CAL02 | Phase 2 | Pneumonia, Bacterial | - | - |
Dantrolene sodium for injectable suspension | Phase 2 | Heat Stroke | - | - |
SeeMore(TM) | Phase 2 | Myocardial Infarction | - | - |
Frequently asked questions
What is in EAGLE PHARMACEUTICALS, INC.'s drug pipeline?→
CatalystAlert tracks 5 drug candidates in EAGLE PHARMACEUTICALS, INC.'s (EGRX) pipeline across Phase 3, Phase 2. Its lead program is Ryanodex and Standard of Care (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is EAGLE PHARMACEUTICALS, INC.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for EAGLE PHARMACEUTICALS, INC. (EGRX) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track EGRX biotech catalysts?→
Add EGRX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow EAGLE PHARMACEUTICALS, INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.